

Electronic Acknowledgement Receipt

EFS ID:	6673702
Application Number:	09854568
International Application Number:	
Confirmation Number:	8438
Title of Invention:	METHODS AND COMPOSITIONS FOR STIMULATING THE IMMUNE SYSTEM
First Named Inventor/Applicant Name:	Samuel Bogoch
Correspondence Address:	KENYON & KENYON - Suite 700 1500 K Street, N.W. Washington DC 20005 US 2022204200 -
Filer:	Qi Zhao/jin li
Filer Authorized By:	Qi Zhao
Attorney Docket Number:	9425/46702
Receipt Date:	21-DEC-2009
Filing Date:	15-MAY-2001
Time Stamp:	12:21:06
Application Type:	Utility under 35 USC 111(a)

Payment information:

Submitted with Payment	yes
Payment Type	Credit Card
Payment was successfully received in RAM	\$1055

RAM confirmation Number	9211				
Deposit Account	110600				
Authorized User	KENYON & KENYON LLP				
<p>The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.16 (National application filing, search, and examination fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)</p> <p>Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)</p>					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Miscellaneous Incoming Letter	Submission.pdf	81636 <small>88c11c0ac7986f7a98f12210fab00ee19a7d3a</small>	no	3
Warnings:					
Information:					
2	Foreign Reference	EP0015755A2.pdf	3602436 <small>369a77c4988b5c576465117886a8f22f908a7c6d8</small>	no	81
Warnings:					
Information:					
3	Foreign Reference	EP0221748A2.pdf	971631 <small>4ad13a1ee68b775f919b37f6488920851d8f6ecb</small>	no	28
Warnings:					
Information:					
4	NPL Documents	Harris.pdf	77219 <small>bd471b192492f3104880117476a8f9884e742688c</small>	no	1
Warnings:					
Information:					
5	NPL Documents	Bogoch-elevated-serum-anti-malignin.pdf	1686267 <small>46fc1c20c98ec32ee5c22aaff7bf51357bc27c2e</small>	no	4
Warnings:					
Information:					
6	NPL Documents	Bogoch-astrocytin-and-malignin.pdf	1433310 <small>1c0519264768946e008ba6745ab72a604c20856</small>	no	8
Warnings:					
Information:					

7	NPL Documents	bogoch-in-vitro-production-of-the-general-transformation.pdf	1910660 650841a83ee316d7a23efb69de426310f343c	no	10
Warnings:					
Information:					
8	NPL Documents	Bogoch-Tumor-Markers.PDF	2421547 f180112a6d290134935c4b9309c16418b94d18	no	18
Warnings:					
Information:					
9	NPL Documents	Knuth.PDF	1426351 4962ca03c71ca47b78795c485a2c5e634eb798f	no	6
Warnings:					
Information:					
10	NPL Documents	bogoch-disarmed-anti-malignin-antibody-in-human-cancer.pdf	151398 9223684915192a854b16444ca2750280534829	no	2
Warnings:					
Information:					
11	NPL Documents	Bogoch-monoclonal-anti-malignin-antibodies.pdf	301721 4e14e9f1da79d8e4e53cc0b03201667d5d603c5	no	4
Warnings:					
Information:					
12	NPL Documents	Bogoch-malignin-antibody-and-early-malignancy.pdf	136609 eb88b34a8a023a55daffa1215f6d760fa1c4119	no	1
Warnings:					
Information:					
13	Issue Fee Payment (PTO-85B)	issuefeetransmittal.pdf	104532 312c92963ec146ff80730ab3ac81c27da7276e42	no	1
Warnings:					
Information:					
14	NPL Documents	Bernards.pdf	1303799 b4b7308c18a17f4859a8fa2a2a859c38dc8c0f84a	no	5
Warnings:					
Information:					
15	Fee Worksheet (PTO-875)	fee-info.pdf	32165 08a8ff974895c756ba1081c5146ae5c5aee7d71e02	no	2
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.